Literature DB >> 18951881

Nitric oxide synthases are crucially involved in the development of the severe cardiomyopathy of caveolin-1 knockout mice.

Carsten Wunderlich1, Kristin Schober, Michael Kasper, Christian Heerwagen, Rainer Marquetant, Bernd Ebner, Matthias Forkmann, Steffen Schoen, Ruediger C Braun-Dullaeus, Alexander Schmeisser, Ruth H Strasser.   

Abstract

Targeted ablation of caveolin-1 (cav-1) results in a severe cardiomyopathy. How the loss of cav-1 mediates these abnormalities is currently under investigation. Mounting evidence indicates that cav-1 acts as a negative regulator of endothelial nitric oxide synthase resulting in a constitutive hyperactivation of the nitric oxide (NO)-pathway in cav-1 knockout mice (cav-1 ko). In this context we hypothesized that disturbed NO signalling is implicated in these changes. To explore this question cav-1 ko were compared with knockout counterparts experiencing 2 month postnatal NO synthase inhibition by N(G)-nitro-l-arginine methyl ester (l-NAME) treatment. Chronic l-NAME treatment resulted in significant improvements in heart function and exercise capacity in cav-1 ko. Furthermore, we found evidence for an enhanced radical stress in hearts of cav-1 ko which was markedly reduced by l-NAME treatment. Collectively, these findings suggest that NO synthases play a crucial role in the evolution of heart failure evident in cav-1 ko.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951881     DOI: 10.1016/j.bbrc.2008.10.068

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice.

Authors:  Pascal Bernatchez; Arpeeta Sharma; Philip M Bauer; Ethan Marin; William C Sessa
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

2.  Altered angiogenesis in caveolin-1 gene-deficient mice is restored by ablation of endothelial nitric oxide synthase.

Authors:  Christudas Morais; Quteba Ebrahem; Bela Anand-Apte; Marie-Odile Parat
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

3.  Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II.

Authors:  Luminita H Pojoga; Jose R Romero; Tham M Yao; Paul Loutraris; Vincent Ricchiuti; Patricia Coutinho; Christine Guo; Nathalie Lapointe; James R Stone; Gail K Adler; Gordon H Williams
Journal:  Endocrinology       Date:  2010-01-22       Impact factor: 4.736

4.  Caveolin as a potential drug target for cardiovascular protection.

Authors:  Stephanie L Sellers; Andy E Trane; Pascal N Bernatchez
Journal:  Front Physiol       Date:  2012-07-18       Impact factor: 4.566

5.  Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.

Authors:  Marta H Krieger; Annarita Di Lorenzo; Christine Teutsch; Katalin Kauser; William C Sessa
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

Review 6.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

7.  A process-based review of mouse models of pulmonary hypertension.

Authors:  Mita Das; Joshua Fessel; Haiyang Tang; James West
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

8.  Myocardial interstitial Cajal-like cells (ICLC) in caveolin-1 KO mice.

Authors:  M Gherghiceanu; M E Hinescu; L M Popescu
Journal:  J Cell Mol Med       Date:  2009-01       Impact factor: 5.310

Review 9.  Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension.

Authors:  Shahood Fazal; Malik Bisserier; Lahouaria Hadri
Journal:  Cells       Date:  2021-03-13       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.